{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:32:27Z","timestamp":1785450747129,"version":"3.56.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Co., Ltd","award":["Takeda (China) International Trading Co., Ltd"],"award-info":[{"award-number":["Takeda (China) International Trading Co., Ltd"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To assess the possible effect of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) on the health-related quality of life (HRQoL) in patients with\n                      <jats:italic>ALK<\/jats:italic>\n                      -positive non-small cell lung cancer (NSCLC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search was performed in PubMed, Web of Science, Embase, and ClinicalTrials.gov to identify literature published between January 2010 and January 2025. Publications reported quantitative assessments of HRQoL in\n                      <jats:italic>ALK<\/jats:italic>\n                      -positive NSCLC patients treated with ALK-TKIs were included. Meta-analyses were performed using random effect models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 805 records were identified, of which 21 were analyzed in the meta-analysis. Compared to crizotinib, next-generation ALK-TKIs showed statistically significant delayed time to deterioration (TTD) in global health status measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) (hazard ratio [HR]: 0.80; 95% confidence interval [CI]: 0.67 to 0.96). Brigatinib and alectinib demonstrated superior TTD in fatigue symptom score of EORTC QLQ-C30 compared to crizotinib (HR: 0.71; 95% CI: 0.54 to 0.92). Regarding between-arm comparisons from baseline, brigatinib and lorlatinib outperformed crizotinib in global health status, physical and emotional functioning, and symptoms scores of nausea and vomiting, fatigue, constipation, and appetite loss using EORTC QLQ-C30.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study is by far the most comprehensive systematic review and meta-analysis on HRQoL among\n                      <jats:italic>ALK<\/jats:italic>\n                      -positive NSCLC patients treated with ALK-TKIs. These findings extended prior literature by conducting a granular comparison of all available ALK-TKIs across multiple endpoints and highlighted the improved performance of next-generation ALK-TKIs in enhancing HRQoL for\n                      <jats:italic>ALK<\/jats:italic>\n                      -positive NSCLC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11136-025-04088-6","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:24:00Z","timestamp":1764325440000},"page":"3073-3092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Yan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"3","key":"4088_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209\u2013249.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"4","key":"4088_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/1759-7714.12613","volume":"9","author":"X Du","year":"2018","unstructured":"Du, X., et al. (2018). ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thoracic Cancer, 9(4), 423\u2013430.","journal-title":"Thoracic Cancer"},{"key":"4088_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863461","volume":"12","author":"L Peng","year":"2022","unstructured":"Peng, L., et al. (2022). Targeting ALK rearrangements in NSCLC: Current state of the art. Frontiers in Oncology, 12, Article 863461.","journal-title":"Frontiers in Oncology"},{"issue":"29","key":"4088_CR4","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon, B. J., et al. (2024). Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. Journal Of Clinical Oncology, 42(29), 3400\u20133409.","journal-title":"Journal Of Clinical Oncology"},{"issue":"11","key":"4088_CR5","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.mayocp.2019.04.005","volume":"94","author":"R Warsame","year":"2019","unstructured":"Warsame, R., & D\u2019Souza, A. (2019). Patient reported outcomes have arrived: A practical overview for clinicians in using patient reported outcomes in oncology. Mayo Clinic Proceedings, 94(11), 2291\u20132301.","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"4088_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11136-015-1099-z","volume":"25","author":"D Kyte","year":"2016","unstructured":"Kyte, D., et al. (2016). International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Quality of Life Research, 25(2), 359\u2013362.","journal-title":"Quality of Life Research"},{"issue":"5","key":"4088_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"4088_CR8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","volume":"30A","author":"B Bergman","year":"1994","unstructured":"Bergman, B., et al. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. European Journal of Cancer, 30A(5), 635\u2013642.","journal-title":"European Journal of Cancer"},{"issue":"3","key":"4088_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40271-024-00683-w","volume":"17","author":"A Gnanasakthy","year":"2024","unstructured":"Gnanasakthy, A., & DeMuro, C. R. (2024). The limitations of EQ-5D as a clinical outcome assessment tool. Patient, 17(3), 215\u2013217.","journal-title":"Patient"},{"issue":"Suppl 1","key":"4088_CR10","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","volume":"29A","author":"PJ Hollen","year":"1993","unstructured":"Hollen, P. J., et al. (1993). Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). European Journal of Cancer, 29A(Suppl 1), S51\u2013S58.","journal-title":"European Journal of Cancer"},{"issue":"2","key":"4088_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229179","volume":"15","author":"J Elliott","year":"2020","unstructured":"Elliott, J., et al. (2020). ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. PLoS ONE, 15(2), Article e0229179.","journal-title":"PLoS ONE"},{"issue":"1","key":"4088_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1186\/s12885-021-08977-0","volume":"21","author":"HC Ma","year":"2021","unstructured":"Ma, H. C., et al. (2021). Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: A meta-analysis of clinical trials. BMC Cancer, 21(1), 1278.","journal-title":"BMC Cancer"},{"key":"4088_CR13","doi-asserted-by":"publisher","DOI":"10.21037\/pcm-22-54","author":"AC Tan","year":"2023","unstructured":"Tan, A. C., et al. (2023). First-line ALK inhibitors in treatment-naive advanced ALK rearranged non-small cell lung cancer: Systematic review and network meta-analysis. Precision Cancer Medicine. https:\/\/doi.org\/10.21037\/pcm-22-54","journal-title":"Precision Cancer Medicine"},{"issue":"4","key":"4088_CR14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.21037\/jtd-23-380","volume":"15","author":"WQ Wang","year":"2023","unstructured":"Wang, W. Q., et al. (2023). A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer. Journal of Thoracic Disease, 15(4), 1935\u20131947.","journal-title":"Journal of Thoracic Disease"},{"issue":"1","key":"4088_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12885-024-11916-4","volume":"24","author":"M Zhao","year":"2024","unstructured":"Zhao, M., et al. (2024). Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: A systematic review and network meta-analysis. BMC Cancer, 24(1), 186.","journal-title":"BMC Cancer"},{"issue":"6","key":"4088_CR16","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.3747\/co.27.6563","volume":"27","author":"BC Tse","year":"2020","unstructured":"Tse, B. C., et al. (2020). Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: A prospective real-world assessment. Current Oncology, 27(6), e552\u2013e559.","journal-title":"Current Oncology"},{"key":"4088_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, Article n71.","journal-title":"BMJ"},{"issue":"7414","key":"4088_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., et al. (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.), 327(7414), 557\u2013560.","journal-title":"BMJ (Clinical research ed.)"},{"issue":"2","key":"4088_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1467-9876.2005.00489.x","volume":"54","author":"K Sidik","year":"2005","unstructured":"Sidik, K., & Jonkman, J. N. (2005). Simple heterogeneity variance estimation for meta-analysis. Journal of the Royal Statistical Society. Series C, Applied Statistics, 54(2), 367\u2013384.","journal-title":"Journal of the Royal Statistical Society. Series C, Applied Statistics"},{"issue":"7","key":"4088_CR20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw, A. T., et al. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 18(7), 874\u2013886.","journal-title":"The Lancet Oncology"},{"issue":"12","key":"4088_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R., et al. (2021). Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial. Journal of Thoracic Oncology, 16(12), 2091\u20132108.","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"4088_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok, T., et al. (2020). Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals Of Oncology, 31(8), 1056\u20131064.","journal-title":"Annals Of Oncology"},{"issue":"21","key":"4088_CR23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T., et al. (2020). First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. The New England Journal of Medicine, 383(21), 2018\u20132029.","journal-title":"The New England Journal of Medicine"},{"issue":"11","key":"4088_CR24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","volume":"7","author":"L Horn","year":"2021","unstructured":"Horn, L., et al. (2021). Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial. JAMA Oncology, 7(11), 1617\u20131625.","journal-title":"JAMA Oncology"},{"issue":"23","key":"4088_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B. J., et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167\u20132177.","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"4088_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0643","volume":"3","author":"N Marschner","year":"2020","unstructured":"Marschner, N., et al. (2020). Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer. JAMA Network Open, 3(3), Article e200643.","journal-title":"JAMA Network Open"},{"issue":"2","key":"4088_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40264-018-0771-y","volume":"42","author":"D Rocco","year":"2019","unstructured":"Rocco, D., et al. (2019). Safety and tolerability of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Drug Safety, 42(2), 199\u2013209.","journal-title":"Drug Safety"},{"key":"4088_CR28","unstructured":"Genentech USA, I. ALECENSA\u00ae (alectinib). (2021). July 20, 2023]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208434s010lbl.pdf"},{"issue":"1","key":"4088_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/jjco\/hyaa192","volume":"51","author":"T Naito","year":"2021","unstructured":"Naito, T., Shiraishi, H., & Fujiwara, Y. (2021). Brigatinib and lorlatinib: Their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Japanese Journal of Clinical Oncology, 51(1), 37\u201344.","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"21","key":"4088_CR30","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge, D. R., et al. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. The New England Journal of Medicine, 379(21), 2027\u20132039.","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"4088_CR31","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","volume":"24","author":"TM Bauer","year":"2019","unstructured":"Bauer, T. M., et al. (2019). Clinical management of adverse events associated with Lorlatinib. The Oncologist, 24(8), 1103\u20131110.","journal-title":"The Oncologist"},{"issue":"10","key":"4088_CR32","doi-asserted-by":"publisher","first-page":"S641","DOI":"10.1016\/j.jtho.2024.09.1208","volume":"19","author":"A Tanzilli","year":"2024","unstructured":"Tanzilli, A., et al. (2024). EP.12B.03 cognitive impact of lorlatinib administration in advanced non small cell lung cancer with ALK and ROS1 fusions. Journal of Thoracic Oncology, 19(10), S641.","journal-title":"Journal of Thoracic Oncology"},{"issue":"25","key":"4088_CR33","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw, A. T., et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine, 368(25), 2385\u20132394.","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"4088_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S., et al. (2017). Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. The New England Journal of Medicine, 377(9), 829\u2013838.","journal-title":"The New England Journal of Medicine"},{"key":"4088_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2020.04.011","volume":"144","author":"D Breadner","year":"2020","unstructured":"Breadner, D., et al. (2020). Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 144, 57\u201363.","journal-title":"Lung Cancer"},{"key":"4088_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754768","volume":"11","author":"L Peng","year":"2021","unstructured":"Peng, L., et al. (2021). Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: A Bayesian network meta-analysis. Frontiers in Oncology, 11, Article 754768.","journal-title":"Frontiers in Oncology"},{"issue":"2\u20133","key":"4088_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0169-5002(00)00179-3","volume":"31","author":"A Montazeri","year":"2001","unstructured":"Montazeri, A., et al. (2001). Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer, 31(2\u20133), 233\u2013240.","journal-title":"Lung Cancer"},{"issue":"5","key":"4088_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/PPO.0b013e3181b9c5b9","volume":"15","author":"PC Trask","year":"2009","unstructured":"Trask, P. C., Hsu, M.-A., & McQuellon, R. (2009). Other paradigms: Health-related quality of life as a measure in cancer treatment: Its importance and relevance. The Cancer Journal, 15(5), 435\u2013440.","journal-title":"The Cancer Journal"},{"key":"4088_CR39","unstructured":"National Comprehensive Cancer Network. (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer [v.3.2025]."},{"key":"4088_CR40","unstructured":"Chinese Society of Clinical Oncology. (2024). Guidelines of Chinese Society of Clinical Oncology (CSCO) Non-Small Cell Lung Cancer."},{"key":"4088_CR41","unstructured":"Chinese Association for Clinical, O., et al. (2024). [China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition)]. Zhonghua Yi Xue Za Zhi. 104(7) 473\u2013485."},{"key":"4088_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-014-0196-y","volume":"13","author":"DT Arnold","year":"2015","unstructured":"Arnold, D. T., et al. (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13, 6.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"12","key":"4088_CR43","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/JTO.0b013e3181f77a6a","volume":"5","author":"RW Jang","year":"2010","unstructured":"Jang, R. W., et al. (2010). Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. Journal of Thoracic Oncology, 5(12), 1953\u20131957.","journal-title":"Journal of Thoracic Oncology"},{"key":"4088_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12955-014-0163-7","volume":"12","author":"I Khan","year":"2014","unstructured":"Khan, I., & Morris, S. (2014). A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: A comparison with existing approaches. Health and Quality of Life Outcomes, 12, 163.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"11","key":"4088_CR45","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","volume":"9","author":"F Blackhall","year":"2014","unstructured":"Blackhall, F., et al. (2014). Patient-reported outcomes and quality of life in PROFILE 1007: A randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 9(11), 1625\u20131633.","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"4088_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000219","volume":"2","author":"F Blackhall","year":"2017","unstructured":"Blackhall, F., et al. (2017). Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2(3), Article e000219.","journal-title":"ESMO Open"},{"issue":"10","key":"4088_CR47","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","volume":"13","author":"YL Wu","year":"2018","unstructured":"Wu, Y. L., et al. (2018). Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. Journal of Thoracic Oncology, 13(10), 1539\u20131548.","journal-title":"Journal of Thoracic Oncology"},{"issue":"10072","key":"4088_CR48","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria, J. C., et al. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study. The Lancet, 389(10072), 917\u2013929.","journal-title":"The Lancet"},{"issue":"4","key":"4088_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jtho.2019.11.006","volume":"15","author":"M Nishio","year":"2020","unstructured":"Nishio, M., et al. (2020). Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC. Journal of Thoracic Oncology, 15(4), 609\u2013617.","journal-title":"Journal of Thoracic Oncology"},{"key":"4088_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.10.002","volume":"138","author":"M Perol","year":"2019","unstructured":"Perol, M., et al. (2019). Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer, 138, 79\u201387.","journal-title":"Lung Cancer"},{"key":"4088_CR51","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.lungcan.2021.03.005","volume":"155","author":"MR Garcia Campelo","year":"2021","unstructured":"Garcia Campelo, M. R., et al. (2021). Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L). Lung Cancer, 155, 68\u201377.","journal-title":"Lung Cancer"},{"key":"4088_CR52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2022.11.004","volume":"174","author":"J Mazieres","year":"2022","unstructured":"Mazieres, J., et al. (2022). Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer, 174, 146\u2013156.","journal-title":"Lung Cancer"},{"issue":"24","key":"4088_CR53","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","volume":"34","author":"L Crino","year":"2016","unstructured":"Crino, L., et al. (2016). Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2. Journal of Clinical Oncology, 34(24), 2866\u20132873.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"4088_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000364","volume":"3","author":"SI Ou","year":"2018","unstructured":"Ou, S. I., et al. (2018). Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. ESMO Open, 3(5), Article e000364.","journal-title":"ESMO Open"},{"issue":"9","key":"4088_CR55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/13696998.2019.1624080","volume":"22","author":"AK Kawata","year":"2019","unstructured":"Kawata, A. K., et al. (2019). Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study. Journal of Medical Economics, 22(9), 924\u2013935.","journal-title":"Journal of Medical Economics"},{"issue":"24","key":"4088_CR56","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.2217\/fon-2019-0185","volume":"15","author":"WR Lenderking","year":"2019","unstructured":"Lenderking, W. R., et al. (2019). Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). Future Oncology, 15(24), 2841\u20132855.","journal-title":"Future Oncology"},{"issue":"12","key":"4088_CR57","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jtho.2022.08.018","volume":"17","author":"SI Ou","year":"2022","unstructured":"Ou, S. I., et al. (2022). Efficacy of brigatinib in patients with advanced ALK-positive NSCLC who progressed on alectinib or ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology, 17(12), 1404\u20131414.","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"4088_CR58","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang, Y., et al. (2020). Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: A multicentre, phase 2 trial. The Lancet Respiratory Medicine, 8(1), 45\u201353.","journal-title":"The Lancet Respiratory Medicine"},{"issue":"12","key":"4088_CR59","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon, B. J., et al. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. The Lancet Oncology, 19(12), 1654\u20131667.","journal-title":"The Lancet Oncology"},{"key":"4088_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8101","author":"E Felip","year":"2015","unstructured":"Felip, E., et al. (2015). Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.8101","journal-title":"Journal of Clinical Oncology"},{"key":"4088_CR61","doi-asserted-by":"crossref","unstructured":"Blackhall, F., Cappuzzo, F., Kim, D.W., Wu, Y., Solomon, B., Nakagawa, K., Mekhail, T., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K., Tursi, J., Mok T. (2014). Impact of crizotinib on patient-reported symptoms and global quality of life (QoL) compared with platinum based chemotherapy in phase III study of treatment na\u00efve advanced ALK-positive non-small cell lung cancer (NSCLC). 25(supplement 4).","DOI":"10.1093\/annonc\/mdu349.5"},{"key":"4088_CR62","first-page":"S799","volume":"49","author":"F Blackhall","year":"2013","unstructured":"Blackhall, F., et al. (2013). Impact of crizotinib on patient-reported general health status compared with single-agent chemotherapy in a phase III study of advanced ALK-positive non-small cell lung cancer (NSCLC). European Journal of Cancer, 49, S799\u2013S800.","journal-title":"European Journal of Cancer"},{"key":"4088_CR63","first-page":"S795","volume":"49","author":"F Blackhall","year":"2013","unstructured":"Blackhall, F., et al. (2013). Impact of crizotinib on patient-reported symptoms and global quality of life (QoL) compared with chemotherapy in a phase III study of advanced alk-positive non-small cell lung cancer (NSCLC). European Journal of Cancer, 49, S795.","journal-title":"European Journal of Cancer"},{"key":"4088_CR64","doi-asserted-by":"publisher","first-page":"ix174","DOI":"10.1093\/annonc\/mdy483.001","volume":"29","author":"C Zhou","year":"2018","unstructured":"Zhou, C., Kim, S. W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J. J., Cheng, Y., Lee, S. H., Bu, L., Xu, T., Yang, L., Wang, C., Morcos, P. N., Mitry, E., & Li, Z. (2018). Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-na\u00efve ALK+ advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 29, ix174.","journal-title":"Annals of Oncology"},{"issue":"3","key":"4088_CR65","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1016\/j.jtho.2021.01.155","volume":"16","author":"G Selvaggi","year":"2021","unstructured":"Selvaggi, G., et al. (2021). FP14.12 Quality of life and subgroup analysis in a phase 3 randomized study of ensartinib vs crizotinib in ALK\u2013positive NSCLC patients: EXalt3. Journal of Thoracic Oncology, 16(3), S232\u2013S233.","journal-title":"Journal of Thoracic Oncology"},{"issue":"57","key":"4088_CR66","doi-asserted-by":"publisher","first-page":"S1056","DOI":"10.1016\/j.annonc.2022.07.1229","volume":"33","author":"G Liu","year":"2022","unstructured":"Liu, G., Reisman, A., Blackhall, F., & Mazieres, J. (2022). Health-related quality of life (HRQOL) in patients with ALK+ non-small cell lung cancer (NSCLC) in the phase III CROWN study. Annals of Oncology, 33(57), S1056.","journal-title":"Annals of Oncology"},{"key":"4088_CR67","doi-asserted-by":"crossref","unstructured":"Mazieres, J., De Castro, J., Migliorino, M. R., Helland, \u00c5., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V., & Oh, I. (2017). Patient-reported outcomes and safety from the phase III ALUR study of Alectinib vs chemotherapy in pre-treated ALK+ NSCLC. Journal of Thoracic Oncology S1897.","DOI":"10.1093\/annonc\/mdx380.048"},{"key":"4088_CR68","doi-asserted-by":"publisher","first-page":"S423","DOI":"10.1016\/j.jval.2020.08.154","volume":"23","author":"L Greillier","year":"2020","unstructured":"Greillier, L., et al. (2020). PCN17 health-related quality of life (HRQOL) of ALK-rearranged non-small cell lung cancer (NSCLC) patients treated in second line with alectinib. Value in Health, 23, S423.","journal-title":"Value in Health"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-04088-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-025-04088-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-025-04088-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T14:01:43Z","timestamp":1765029703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-025-04088-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4088"],"URL":"https:\/\/doi.org\/10.1007\/s11136-025-04088-6","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Li Zhang: Member of advisory council\/committees for Takeda; Honoraria of Takeda. Yan Huang: Honoraria of Takeda. Qian Chu: Honoraria of Takeda. Jiejun Wang has no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}